Replimune Group Inc (NASDAQ:REPL) was the target of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 1,370,700 shares, a decline of 5.1% from the May 15th total of 1,444,700 shares. Approximately 17.2% of the shares of the company are short sold. Based on an average daily volume of 47,400 shares, the days-to-cover ratio is presently 28.9 days.
Shares of Replimune Group stock traded down $0.53 on Friday, reaching $12.11. 24,717 shares of the company were exchanged, compared to its average volume of 49,736. Replimune Group has a fifty-two week low of $8.88 and a fifty-two week high of $23.55. The company has a debt-to-equity ratio of 0.05, a current ratio of 14.26 and a quick ratio of 14.26. The stock has a market cap of $383.45 million and a price-to-earnings ratio of -9.11. The business has a fifty day simple moving average of $13.35.
REPL has been the subject of a number of analyst reports. Zacks Investment Research upgraded HB Fuller from a “sell” rating to a “hold” rating in a research report on Wednesday, July 3rd. Wedbush cut their target price on Eiger Biopharmaceuticals from $43.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 24th. JPMorgan Chase & Co. reissued a “buy” rating and issued a $69.00 price objective on shares of Daimler in a research note on Friday, July 12th. Finally, HC Wainwright set a $73.00 price objective on Uniqure and gave the stock a “buy” rating in a research note on Monday, July 8th. Six equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $24.67.
About Replimune Group
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
See Also: What is systematic risk?
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.